429 related articles for article (PubMed ID: 28157703)
1. Discovery and validation of potential urinary biomarkers for bladder cancer diagnosis using a pseudotargeted GC-MS metabolomics method.
Zhou Y; Song R; Ma C; Zhou L; Liu X; Yin P; Zhang Z; Sun Y; Xu C; Lu X; Xu G
Oncotarget; 2017 Mar; 8(13):20719-20728. PubMed ID: 28157703
[TBL] [Abstract][Full Text] [Related]
2. The development of plasma pseudotargeted GC-MS metabolic profiling and its application in bladder cancer.
Zhou Y; Song R; Zhang Z; Lu X; Zeng Z; Hu C; Liu X; Li Y; Hou J; Sun Y; Xu C; Xu G
Anal Bioanal Chem; 2016 Sep; 408(24):6741-9. PubMed ID: 27473428
[TBL] [Abstract][Full Text] [Related]
3. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery.
Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z
J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
5. Urinary metabolomics for discovering metabolic biomarkers of bladder cancer by UPLC-MS.
Wang R; Kang H; Zhang X; Nie Q; Wang H; Wang C; Zhou S
BMC Cancer; 2022 Feb; 22(1):214. PubMed ID: 35220945
[TBL] [Abstract][Full Text] [Related]
6. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
7. Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up.
Critelli R; Fasanelli F; Oderda M; Polidoro S; Assumma MB; Viberti C; Preto M; Gontero P; Cucchiarale G; Lurkin I; Zwarthoff EC; Vineis P; Sacerdote C; Matullo G; Naccarati A
Oncotarget; 2016 Oct; 7(41):67435-67448. PubMed ID: 27611947
[TBL] [Abstract][Full Text] [Related]
8. UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
Wang Z; Liu X; Liu X; Sun H; Guo Z; Zheng G; Zhang Y; Sun W
BMC Cancer; 2019 Dec; 19(1):1195. PubMed ID: 31805976
[TBL] [Abstract][Full Text] [Related]
9. Discovery of urine biomarkers for bladder cancer via global metabolomics.
Shi H; Li X; Zhang Q; Yang H; Zhang X
Biomarkers; 2016 Nov; 21(7):578-88. PubMed ID: 27133288
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive urinary metabonomic diagnosis of human bladder cancer.
Pasikanti KK; Esuvaranathan K; Ho PC; Mahendran R; Kamaraj R; Wu QH; Chiong E; Chan EC
J Proteome Res; 2010 Jun; 9(6):2988-95. PubMed ID: 20337499
[TBL] [Abstract][Full Text] [Related]
11. Development of a universal metabolome-standard method for long-term LC-MS metabolome profiling and its application for bladder cancer urine-metabolite-biomarker discovery.
Peng J; Chen YT; Chen CL; Li L
Anal Chem; 2014 Jul; 86(13):6540-7. PubMed ID: 24877652
[TBL] [Abstract][Full Text] [Related]
12. Combined use of epithelial membrane antigen and nuclear matrix protein 52 as sensitive biomarkers for detection of bladder cancer.
Attallah AM; El-Far M; Abdallah SO; El-Waseef AM; Omran MM; Abdelrazek MA; Attallah AA; Saadh MJ; Radwan M; El-waffaey KA; Abol-Enei H
Int J Biol Markers; 2015 Nov; 30(4):e407-13. PubMed ID: 26349665
[TBL] [Abstract][Full Text] [Related]
13. Three serum metabolite signatures for diagnosing low-grade and high-grade bladder cancer.
Tan G; Wang H; Yuan J; Qin W; Dong X; Wu H; Meng P
Sci Rep; 2017 Apr; 7():46176. PubMed ID: 28382976
[TBL] [Abstract][Full Text] [Related]
14. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
15. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer.
Liu H; He W; Wang B; Xu K; Han J; Zheng J; Ren J; Shao L; Bo S; Lu S; Lin T; Huang J
BMC Cancer; 2018 Jun; 18(1):659. PubMed ID: 29907142
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic role of survivin in urinary bladder cancer.
Srivastava AK; Singh PK; Srivastava K; Singh D; Dalela D; Rath SK; Goel MM; Brahma Bhatt ML
Asian Pac J Cancer Prev; 2013; 14(1):81-5. PubMed ID: 23534808
[TBL] [Abstract][Full Text] [Related]
17. Urinary metabolite and lipid alterations in Colombian Hispanic women with breast cancer: A pilot study.
Cala M; Aldana J; Sánchez J; Guio J; Meesters RJW
J Pharm Biomed Anal; 2018 Apr; 152():234-241. PubMed ID: 29428809
[TBL] [Abstract][Full Text] [Related]
18. Urinary Metabolomic Profiling to Identify Potential Biomarkers for the Diagnosis of Behcet's Disease by Gas Chromatography/Time-of-Flight-Mass Spectrometry.
Ahn JK; Kim J; Hwang J; Song J; Kim KH; Cha HS
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099052
[TBL] [Abstract][Full Text] [Related]
19. Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry.
Pasikanti KK; Esuvaranathan K; Hong Y; Ho PC; Mahendran R; Raman Nee Mani L; Chiong E; Chan EC
J Proteome Res; 2013 Sep; 12(9):3865-73. PubMed ID: 23885889
[TBL] [Abstract][Full Text] [Related]
20. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]